Whole Live Micro-organism, Cell, Or Virus Containing Patents (Class 424/93.1)
  • Patent number: 11447797
    Abstract: The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: September 20, 2022
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Service
    Inventors: John A. Chiorini, Giovanni Di Pasquale, Randy Chandler, Charles P. Venditti
  • Patent number: 11435350
    Abstract: The invention provides cellular compositions that contain CD34+ cells derived from bone marrow of a decease donor and CD3+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: September 6, 2022
    Assignee: MEDEOR THERAPEUTICS, INC.
    Inventors: Michael Zdanowski, Colby Suire, D. Scott Batty, Jr.
  • Patent number: 11413252
    Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.
    Type: Grant
    Filed: April 21, 2018
    Date of Patent: August 16, 2022
    Assignee: Coastar Therapeutics Inc.
    Inventor: Eddie Yocon Chung
  • Patent number: 11406478
    Abstract: A biomimetic composite material includes a bioactive cement material, an autologous dentin matrix, and an inorganic nano-reinforcement material. A dental implant includes a body including a biomimetic composite material, wherein the biomimetic composite material includes a bioactive cement material, an autologous dentin matrix, and an inorganic nano-reinforcement material.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: August 9, 2022
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Amir Fakhrzadeh, Mohammad Ali Saghiri
  • Patent number: 11399546
    Abstract: The invention relates to a therapeutic or non-therapeutic use of protozoans, for examples protozoans of the Willaertia magna amoeba species, as a fungistatic and/or fungicide.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 2, 2022
    Assignee: AMOEBA
    Inventors: Fabrice Plasson, Mouh Oulhadj Mameri
  • Patent number: 11376113
    Abstract: The present disclosure relates to a graft material including a reinforced layer and to implantable medical devices including such a graft material. The invention also relates to methods of using and manufacturing such graft materials and devices. In one embodiment the implantable medical device is a stent graft.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: July 5, 2022
    Assignee: Cook Medical Technologies LLC
    Inventor: Ralf Spindler
  • Patent number: 11324855
    Abstract: A cell-free combination for use in the controlled, especially decelerated or retarded, release of active ingredient and/or in the production of a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or as a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or for the coating of a medical product, especially implant, preferably with a formulation in hydrogel form, especially depot formulation in hydrogel form, wherein the cell-free combination comprises a first component and a second component, the first component comprising crosslinkable albumin and the second component comprising a crosslinking agent for the albumin. Additionally, a hydrogel-forming material or hydrogel, to a kit or multicomponent system, to a medical product or a pharmaceutical formulation, to a discharge device, and to uses of the cell-free combination and of the hydrogel-forming material or hydrogel.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: May 10, 2022
    Assignee: TETEC Tissue Engineering Technologies AG
    Inventors: Christoph Gaissmaier, Nils Clausen, Karin Benz
  • Patent number: 11299724
    Abstract: The invention relates to molecular biology, biotechnology, medicine, veterinary science. A group of inventions is proposed: a fusion protein comprising a ligand to MATN1 protein, and a growth factor of EGF, TGF, FGF, IGF, connected via a flexible link; such fusion protein further comprising the Fc-fragment of an antibody or a polypeptide binding with FcRn and/or transferrin or a fragment thereof, connected via a flexible link; encoding polynucleotide, a genetic construct for the synthesis of the fusion protein in producer cells, or cells of a target organism, the fusion protein producer, a producer of the genetic construct, a preparation for the regeneration of cartilage containing at least 1 fusion protein or genetic construct, for parenteral or, in the case of the preparation based on at least 1 fusion protein containing the transport domain, —oral administration, in the latter case the preparation is enclosed in an enteric coating.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 12, 2022
    Assignee: LIMITED LIABILITY COMPANY BIOCHEMICAL AGENT
    Inventors: Ilya Vladimirovich Dukhovlinov, Ekaterina Alekseevna Fedorova
  • Patent number: 11291695
    Abstract: The present invention provides a Bacillus subtilis strain selected from the group consisting of a) the strain deposited as DSM32324, b) the strain deposited as DSM32325, and c) a mutant strain of (a) or (b) which has sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol; and has inhibitory activity against E. coli and Clostridium perfringens. The invention further relates to Bacillus compositions comprising at least one Bacillus subtilis strain of the invention, preferably the Bacillus subtilis strain DSM32324 and/or the Bacillus subtilis strain DSM32325, as Direct Fed Microbial (DFM), premix, animal feed additive or animal feed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 5, 2022
    Assignee: CHR. HANSEN A/S
    Inventors: Dorthe Sandvang, Tina Styrishave
  • Patent number: 11291612
    Abstract: A biomimetic composite material includes a bioactive cement material, an autologous dentin matrix, and an inorganic nano-reinforcement material. A dental implant includes a body including a biomimetic composite material, wherein the biomimetic composite material includes a bioactive cement material, an autologous dentin matrix, and an inorganic nano-reinforcement material.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 5, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Amir Fakhrzadeh, Mohammad Ali Saghiri
  • Patent number: 11275028
    Abstract: Methods and apparatus for rapid, culture and/or label free pathogen detection. The methods utilize optical spectroscopy techniques to identify and/or characterize pathogens in a sample via the detection of unique properties and/or analytes that are specific to particular pathogens.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: March 15, 2022
    Assignee: STC.UNM
    Inventors: Aaron Kurt Neumann, Anatoliy O Pinchuk, Ke Jiang
  • Patent number: 11242521
    Abstract: The present invention relates to a strain of Salmonella enteritidis 3934vac, which has been deleted the waaL gene to obtain a rough phenotype (3934vac DwaaL), the obtaining procedure and the oligos used with the objective of reducing toxicity and maintaining immunogenicity for its application as a vaccine. Another aspect of the present invention relates to a strain of Salmonella enteritidis 3934vac DwaaL, i.e. rough type, which has been modified to express the gene of the avian adenovirus type I fiber, in addition to the procedure for obtaining a Salmonella enteritidis 3034 vac DwaaL strain expressing an AvA-I fiber gene. The invention also comprises the development of a new, live, recombinant, effective and innocuous avian vaccine against the AvA-I virus developed via an insertion and integration process of AvA-I fiber genes in the chromosome of an attenuated and non-pathogenic strain of the bacterium Salmonella enteritidis.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 8, 2022
    Inventor: Cristina Latasa Osta
  • Patent number: 11235009
    Abstract: The present invention provides a method of improving the phenomenon of the glomerular sclerosis and mononuclear leukocyte infiltration around renal tissues, and increasing the renal function by administering the probiotic bacterium of a Parabacteroides goldsteinii to a subject in need to inhibit the occurrence of chronic kidney disease. The Parabacteroides goldsteinii can also effectively modulate the gene expression level of MCP-1, IL-1?, COL3A, COL6A1, ACAA2, PPAR-?, CPT1, and PGC-1? in kidney tissues to reduce kidney inflammation and renal fibrosis and enhance the mitochondria activity of kidney cells. Therefore, the Parabacteroides goldsteinii of the present invention can be utilized in pharmaceutical compositions for inhibiting or treating chronic kidney diseases.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: February 1, 2022
    Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED
    Inventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai
  • Patent number: 11162077
    Abstract: The present invention relates to an apicidin composition for inducing differentiation of mesenchymal stem cells into cardiac-committed cells, and a method for inducing differentiation into cardiac-committed cells using the same. The present invention allows mesenchymal stem cells to be specifically induced to differentiate into cardiac-committed cells even when an apicidin is treated for only a very short period of time of 24 hours, thereby being capable of solving the extremely low cardiomyogenic differentiation efficiency of mesenchymal stem cells, high cost, and long-term problems in the conventional art, and thus the present invention can be usefully used for treating heart disease.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: November 2, 2021
    Inventors: Youngkeun Ahn, Yong Sook Kim, Dong Im Cho
  • Patent number: 11160852
    Abstract: The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: November 2, 2021
    Assignee: Mirror Biologics, Inc.
    Inventor: Michael Har-Noy
  • Patent number: 11147899
    Abstract: The present invention provides an implant which includes: (a) an autologous engineered tissue; and (b) a vasculature, wherein the engineered tissue is a porous scaffold embedded with endothelial cell, a fibroblast, a myoblast, a mesenchymal cell, an adipocyte, or any combination thereof, wherein the vasculature feeds the cells. Further, the invention provides a method for treating a subject afflicted with a large soft tissue defect by implanting the implant of the invention.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: October 19, 2021
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Shulamit Levenberg, Dana Egozi, Jacob Koffler, Yulia Shandalov-Levi
  • Patent number: 11147843
    Abstract: The present invention provides a method of preventing or treating obesity by administering the probiotic bacterium of a novel Parabacteroides goldsteinii strain to the subject in need. The novel Parabacteroides goldsteinii strain is derived from the gastrointestinal tract of an individual and has better aero-tolerance and better acid-tolerance therefore it has better environmental tolerance to adapt to different living environments. The novel Parabacteroides goldsteinii strain not only can effectively prevent the weight gain of the individual, but also can effectively slow down the weight gain of the obese individual; therefore, the novel Parabacteroides goldsteinii strain of the present invention can be used for preparing a pharmaceutical composition for prevention and/or treating obesity.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: October 19, 2021
    Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED
    Inventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai, Tzu-Lung Lin
  • Patent number: 11130932
    Abstract: An organic liquid and foaming soap composition and dispenser for use as a human hand, body wash and a pet wash, comprising: a) a foam-able organic liquid soap composition comprising the anti-microbial active ingredients of: organic shea butter; USDA approved natural spearmint oil; USDA approved natural lime oil; organic thyme oil; organic rosemary extract; and, b) a portable or fixed, manual or automatic foaming soap dispenser. The organic soap composition may further comprise a base soap comprising: saponified organic coconut oil; organic olive oil; organic sunflower oil; organic jojoba oil; organic aloe vera; and glycerin. And the organic soap composition has a shelf-life of about three years, and able to eradicate about 74.6% through 77.6% of the bacterial strain Staphylococcus aureus after at least one minute of direct contact with the composition. The dispenser is a fixed wall or sink mounted, or a portable bottle, including a mini-foaming leave-on sanitizer.
    Type: Grant
    Filed: September 7, 2020
    Date of Patent: September 28, 2021
    Assignee: Got Green? LLC
    Inventor: Eileen E. Fedyna
  • Patent number: 11123374
    Abstract: The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells. Provided herein are a population of oligodendrocyte progenitor cells (OPCs) derived from pluripotent stem cells, methods of generating the same for use in the treatment of acute spinal cord injury and other conditions affecting the CNS, and containers including the population of OPCs.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: September 21, 2021
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Edward D. Wirth, III, Jane S. Lebkowski, Nathan C. Manley
  • Patent number: 11110154
    Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: September 7, 2021
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Seung Kwak, Ignacio Munoz-Sanjuan, H. Steve Zhang
  • Patent number: 11103582
    Abstract: Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 31, 2021
    Assignee: IMMUSOFT CORPORATION
    Inventors: R. Scott McIvor, Perry B. Hackett, Jason Bell, Myra Christine Urness-Rusten, Elena Aronovich, David W. Hunter
  • Patent number: 11090339
    Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Celularity Inc.
    Inventors: Uri Herzberg, Jodi P. Gurney, Robert J. Hariri
  • Patent number: 11090332
    Abstract: Disclosed are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 17, 2021
    Assignee: Regen Biopharma, Inc.
    Inventors: David Koos, Thomas Ichim
  • Patent number: 11072780
    Abstract: Methods for generating high-yield, high-purity cardiac fibroblasts are described. Differentiation methods comprising chemically defined culture conditions and methods for in vitro maintenance of human pluripotent stem cell-derived cardiac fibroblasts are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 27, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Timothy Joseph Kamp, Jianhua Zhang
  • Patent number: 11058729
    Abstract: Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed method use exosomes and/or miRNA.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: July 13, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stanislav Ivanovich Tomarev, Benjamin Frank John Martin Mead
  • Patent number: 11052118
    Abstract: The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 6, 2021
    Assignee: Fate Therapeutics, Inc.
    Inventors: Daniel Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
  • Patent number: 11027013
    Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 8, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
  • Patent number: 11027024
    Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's deep cerebella nuclei a recombinant adeno-associated virus (rAAV) particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic agent inserted between a pair of AAV inverted terminal repeats in a manner effective to infect the CNS cell of the non-rodent mammal such that the CNS cell expresses the therapeutic agent in the non-rodent mammal.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: June 8, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Beverly L. Davidson, Megan S. Keiser
  • Patent number: 11014975
    Abstract: Factor VIII variants and methods of use thereof are disclosed. In particular embodiments, Factor VIII variants are expressed more efficiently by cells over wild-type Factor VIII proteins, are secreted at increased levels by cells over wild-type Factor VIII proteins, exhibit enhanced activity over wild-type Factor VIII proteins and are packaged more efficiently into viral vectors.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 25, 2021
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Denise Sabatino, Katherine A. High, Liron Elkouby
  • Patent number: 10993443
    Abstract: Provided herein are isolated yield enhancing Methylobacterium sp., compositions comprising yield enhancing Methylobacterium sp., methods of using the compositions to increase yield of soybean plants, plant parts, and soybean plants derived therefrom, and methods of making the compositions. Such yield enhancing Methylobacterium sp. are in certain instances referred to herein as simply “Methylobacterium”. In certain embodiments, yield enhancing Methylobacterium sp. can be distinguished from other yield neutral or yield negative Methylobacterium by assaying the Methylobacterium sp. for improved yield in a controlled environment (i.e. a growth chamber or greenhouse) or in a field test in comparison to untreated control plants.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 4, 2021
    Assignee: NewLeaf Symbiotics, Inc.
    Inventors: Marcus Jones, Gregg Bogosian
  • Patent number: 10973898
    Abstract: The present invention is directed to a method of treating poultry hatchlings in a hatchling tray. The method comprises of providing a soft gel form capable of being dispensed through a spray nozzle, providing a spray dispensing apparatus, the apparatus being capable of delivering a predetermined volume of the gel as a plurality of small beadlets through a plurality of nozzles, placing the hatchling tray containing the hatchlings beneath the nozzles of the dispensing apparatus, dispensing the predetermined volume of the soft gel containing the therapeutic agent as small beadlets into the hatchling tray and allowing the hatchlings to consume the beadlets. The present invention is also directed to a dispensing apparatus for dispensing a therapeutic agent in a soft gel into a hatchling tray of poultry hatchlings.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 13, 2021
    Assignee: CEVA ANIMAL HEALTH INC.
    Inventor: Eng-Hong Lee
  • Patent number: 10973956
    Abstract: The present disclosure relates generally to biomaterial implants and methods for delivering a cell to an individual in need thereof and, more particularly, to biomaterial implants and techniques for delivering islets and/or ?-cell progenitors to an individual.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tadas Kasputis, Michael Skoumal, Lonnie D. Shea
  • Patent number: 10960074
    Abstract: A process for treating glaucoma whereby the treatment can be accomplished by the use of medication or by surgery, or both, in order to control or prevent the occurrence of glaucoma. The optic nerve is aligned within and between two distinct pressurized spaces and within the dural sheath, the intraocular space and the intracranial space having an intraocular pressure (IOP) and an intracranial pressure (ICP), respectively. Medicine can be administered to raise the intracranial pressure in order to reach a desirable lower translaminar pressure difference across these two pressurized spaces which are separated by the lamina cribrosa in order to treat glaucoma. An alternate closely related mode of the treatment process is the implanting of a shunt substantially between the intraocular space and the intracranial space in order to beneficially equalize pressure differentials across the intraocular space and the intracranial space.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: March 30, 2021
    Inventor: John Berdahl
  • Patent number: 10918738
    Abstract: In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient a
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: February 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: H. Kirk Hammond, Mei Hua Gao
  • Patent number: 10894946
    Abstract: The invention is directed to a method for the preparation of a multiring engineered heart tissue construct suitable for use in cardiac tissue augmentation and/or replacement therapy. The invention further refers to multiring EHT constructs which comprise at least two force-generating engineered heart tissue rings fused with each other and a device for preparing the same. Finally, the invention relates to force-generating engineered heart tissue rings derived from human cells and their use in drug screening and target validation assays.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: January 19, 2021
    Assignee: Tissue Systems Holding GmbH
    Inventors: Wolfram-Hubertus Zimmermann, Thomas Eschenhagen
  • Patent number: 10842857
    Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 24, 2020
    Assignee: DUKE UNIVERSITY
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Patent number: 10834942
    Abstract: The invention is directed to compositions and methods are disclosed for improving production of swine. In one embodiment the composition may include a combination of at least one of a biologically pure culture of Bacillus strains. The composition may comprise a Saccharomyces cerevisiae yeast product. Methods are disclosed for providing beneficial effects to swine and their offspring, including but not limited to improved performance of the swine.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 17, 2020
    Assignee: Church & Dwight Co., Inc.
    Inventors: Mari Ellen Davis, Kim Friesen, Thomas G. Rehberger, Ran Song
  • Patent number: 10828336
    Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 10, 2020
    Assignee: Northern Therapeutics Inc.
    Inventor: Duncan John Stewart
  • Patent number: 10801015
    Abstract: The present invention features assays for co-culturing primary cells while maintaining key biological activities specific to the primary cells. The invention is based, at least in part, on the discovery that compositions and methods for primary cells in a high-throughput co-culture platform, image analysis for distinguishing cells in co-cultures and assays that are suitable for screening of agents in epithelial cells, such as hepatocytes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 13, 2020
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Sangeeta Bhatia, Jing Shan, Anne Carpenter Van Dyk, David Logan, Nathan Ross
  • Patent number: 10792353
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 6, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Patent number: 10779519
    Abstract: The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 22, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Steven A. Goldman, Martha Windrem
  • Patent number: 10772333
    Abstract: A composition and methods of using the composition for the control of mollusks are provided, which include an effective amount of one or more isolated Phasmarhabditis nematodes, wherein at least one of the isolated nematodes is P. californica, P. papillosa or P. hermaphrodita, and wherein the P. hermaphrodita does not comprise Moraxella osloensis.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Irma Tandingan De Ley, Rory McDonnell, Timothy Paine
  • Patent number: 10758655
    Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Barbara Ann Huibregtse, Thomas John Herbst, Craig Stolen, Eric M. Schneider, Lynne E. Swanson, Lili Liu
  • Patent number: 10736922
    Abstract: Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34+ bone marrow mesenchymal stem cells. Also disclosed are bone marrow mesenchymal stem cells treated with a telomerase induction agent.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 11, 2020
    Assignee: University of Southern California
    Inventors: Songtao Shi, Kentaro Akiyama, Chider Chen
  • Patent number: 10731136
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or ongogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 4, 2020
    Inventor: Per Sonne Holm
  • Patent number: 10695404
    Abstract: Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1-binding protein, a ?-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • Patent number: 10688151
    Abstract: The invention relates to a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium. The peptide, polypeptide, or protein can be a component of a viral capsid and can be used to lead a recombinant viral vector selectively to the lung endothelial tissue after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention thus further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid comprising the peptide, polypeptide, or protein according to the invention and which comprises at least one transgene packaged in the capsid. The viral vector is suitable in particular for the therapeutic treatment of a lung disorder or a lung disease. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: June 23, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Trepel, Jakob Koerbelin, Stefan Michelfelder
  • Patent number: 10676747
    Abstract: An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 9, 2020
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • Patent number: 10669526
    Abstract: The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 2, 2020
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Chul Won Ha, Jin A. Kim
  • Patent number: 10639336
    Abstract: The present invention provides a composition for preventing stroke and ameliorating the severity of stroke and comprises an effective dose of Lactobacillus reuteri GMNL-89 and Lactobacillus paracasei GMNL-133; the accession number of Lactobacillus reuteri GMNL-89 is CCTCC M207154 and the accession number of Lactobacillus paracasei GMNL-133 is CCTCC M2011331. The composition can be taken as a dietary supplement and be given continuously after a stroke, and said composition has the effects of ameliorating cerebral infarction, motor function, and intestinal microbiota after a stroke.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: May 5, 2020
    Assignee: GENMONT BIOTECH INCORPORATION
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Shiang-Suo Huang, Yi-Hsin Wang